Imagabalin

Summary

Imagabalin (CHEMBL2103836) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including anxiety and generalized anxiety disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 13
• Chemistry: 173.25 Da · C9H19NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103836
Name	Imagabalin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10236037
Molecular formula	C9H19NO2
Molecular weight	173.25
InChIKey	JXEHXYFSIOYTAH-SFYZADRCSA-N

SMILES: CCC[C@@H](C)C[C@@H](CC(=O)O)N

IUPAC name: (3S,5R)-3-amino-5-methyloctanoic acid

Also known as: Imagabalin, Imagabalina, Imagabaline, PD 0332334, PD-0332334, PD0332334, PF-00195889, IMAGABALIN

Parent form; salt/anhydrous children: CHEMBL2105673

Patent coverage: 237 distinct patent families (886 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
generalized anxiety disorder	3	MONDO:0001942	EFO:1001892
kidney failure	1	MONDO:0001106	HP:0000083

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	6
PHASE1	6
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00542685	PHASE3	COMPLETED	A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
NCT00658008	PHASE3	TERMINATED	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
NCT00658372	PHASE3	TERMINATED	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
NCT00658762	PHASE3	TERMINATED	A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
NCT00735267	PHASE3	TERMINATED	A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
NCT00738738	PHASE3	WITHDRAWN	6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
NCT00921063	PHASE2	COMPLETED	A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
NCT00537615	PHASE1	COMPLETED	An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
NCT00721422	PHASE1	TERMINATED	A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
NCT00730145	PHASE1	COMPLETED	A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
NCT00800280	PHASE1	TERMINATED	Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
NCT00809536	PHASE1	TERMINATED	Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00820794	PHASE1	WITHDRAWN	A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).